591805
CD274, Durvalumab Biosimilar (B7-H1, PDL1)
Size
£384.00
- SKU:
- 591805
- Purity:
- ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Human
- Immunogen:
- Recombinant protein corresponding to human CD274, an Adalimumab biosimilar produced in CHO stable cell line.
- Format:
- Supplied as a 0.2uM filtered solution, pH 6.0. No stabilizers or preservatives added.
- Extra Details:
- Durvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1). Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50 of 0.1 and 0.04 nM, respectively. Durvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells. In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner. In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size. Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Durvalumab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice